Posted by Michael Wonder on 18 Sep 2023
Kymera Therapeutics receives US FDA fast track designation for KT-333, a first in class, investigational STAT3 degrader for the treatment of relapsed/refractory cutaneous T-cell lymphoma and relapsed/refractory peripheral T-cell lymphoma
18 September 2023 - KT-333 Phase 1 oncology trial ongoing with an update including initial evaluation of its clinical anti-tumour activity in patients expected in the fourth quarter of 2023.
Kymera Therapeutics today announced that the US FDA has granted fast track designation to KT-333 for the treatment of relapsed/refractory cutaneous T-cell lymphoma and relapsed/refractory peripheral T-cell lymphoma.
